Nalu Navarro-Alvarez

Dr. Nalu Navarro-Alvarez

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Ciudad de México, Mexico
+2
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2009 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
HBHesham Basma
Hesham Basma
ASAlejandro Soto–Gutiérrez
Alejandro Soto–Gutiérrez
GYGovardhana Rao Yannam
Govardhana Rao Yannam
LLLiping Liu
Liping Liu
RIRyotaro Ito
Ryotaro Ito
IFIra J. Fox
Ira J. Fox

1 November 2006 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
ASAlejandro Soto-Gutiérrez
Alejandro Soto-Gutiérrez
NKNaoya Kobayashi
Naoya Kobayashi
JRJorge David Rivas-Carrillo
Jorge David Rivas-Carrillo
NNNalu Navarro-Alvarez
Nalu Navarro-Alvarez
DZDebaio Zhao
Debaio Zhao
IFIra J Fox
Ira J Fox

1 October 2010 in Molecular Therapy
Verified
Journal Article
Open access
HYHiroshi Yagi
Hiroshi Yagi
ASAlejandro Soto-Gutierrez
Alejandro Soto-Gutierrez
NNNalu Navarro-Alvarez
Nalu Navarro-Alvarez
YNYaakov Nahmias
Yaakov Nahmias
YGYoni Goldwasser
Yoni Goldwasser
MYMartin L Yarmush
Martin L Yarmush
Excessive systemic inflammation following trauma, sepsis, or burn could lead to distant organ damage. The transplantation of bone marrow stromal cells or mesenchymal stem cells (MSCs) has been reported to be an effective treatment for several immune disorders by modulating the inflammatory response to injury. We hypothesized that MSCs can dynamically secrete systemic factors that can neutralize the activity of inflammatory cytokines. In this study, we showed that cocultured MSCs are able to decrease nuclear factor κ-B (NFκB) activation in target epithelial cells incubated in inflammatory serum conditions. Proteomic screening revealed a responsive secretion of soluble tumor necrosis factor (TNF) receptor 1 (sTNFR1) when MSCs were exposed to lipopolysaccharide (LPS)-stimulated rat serum. The responsive effect was eliminated when NFκB activation was blocked in MSCs. Intramuscular transplantation of MSCs in LPS-endotoxic rats decreased a panel of inflammatory cytokines and inflammatory infiltration of macrophages and neutrophils in lung, kidney, and liver when compared to controls. These results suggest that improvements of inflammatory responses in animal models after local transplantation of MSCs are at least, in part, explained by the NFκB-dependent secretion of sTNFR1 by MSCs.

25 September 2005 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
MNMichiki Narushima
Michiki Narushima
NKNaoya Kobayashi
Naoya Kobayashi
TOTeru Okitsu
Teru Okitsu
YTYoshihito Tanaka
Yoshihito Tanaka
SLShun-Ai Li
Shun-Ai Li
JYJi-Won Yoon
Ji-Won Yoon

1 November 2006 in Cell Transplantation
Verified
Journal Article
Open access
HMHaruo Misawa
Haruo Misawa
NKNaoya Kobayashi
Naoya Kobayashi
ASAlejandro Soto-Gutierrez
Alejandro Soto-Gutierrez
YCYong Chen
Yong Chen
AYAki Yoshida
Aki Yoshida
TOToshifumi Ozaki
Toshifumi Ozaki
Artificial bones have often used for bone regeneration due to their strength, but they cannot provide an adequate environment for cell penetration and settlement. We therefore attempted to explore various materials that may allow the cells to penetrate and engraft in bone defects. PuraMatrix™ is a self-assembling peptide scaffold that produces a nanoscale environment allowing both cellular penetration and engraftment. The objective of this study was to investigate the effect of PuraMatrix™ on bone regeneration in a mouse bone defect model of the calvaria. Matrigel™ was used as a control. The expression of bone-related genes (alkaline phosphatase, Runx2, and Osterix) in the PuraMatrix™-injected bone defects was stronger than that in the Matrigel™-injected defects. Soft X-ray radiographs revealed that bony bridges were clearly observed in the defects treated with PuraMatrix™, but not in the Matrigel™-treated defects. Notably, PuraMatrix™ treatment induced mature bone tissue while showing cortical bone medullary cavities. The area of newly formed bones at the site of the bone defects was 1.38-fold larger for PuraMatrix™ than Matrigel™. The strength of the regenerated bone was 1.72-fold higher for PuraMatrix™ (146.0 g) than for Matrigel™ (84.7 g). The present study demonstrated that PuraMatrix™ injection favorably induced functional bone regeneration.

10 May 2017 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
JSJ. A. Shah
J. A. Shah
MPM. S. Patel
M. S. Patel
NENahel Elias
Nahel Elias
NNNalu Navarro-Alvarez
Nalu Navarro-Alvarez
IRI. Rosales
I. Rosales
PVP. A. Vagefi
P. A. Vagefi
Since the first attempt of pig‐to‐primate liver xenotransplantation (LXT) in 1968, survival has been limited. We evaluated a model utilizing α‐1,3‐galactosyltransferase knockout donors, continuous posttransplant infusion of human prothrombin concentrate complex, and immunosuppression including anti–thymocyte globulin, FK‐506, methylprednisone, and costimulation blockade (belatacept, n = 3 or anti‐CD40 mAb, n = 1) to extend survival. Baboon 1 remained well until postoperative day (POD) 25, when euthanasia was required because of cholestasis and plantar ulcers. Baboon 2 was euthanized following a seizure on POD 5, despite normal liver function tests (LFTs) and no apparent pathology. Baboon 3 demonstrated initial stable liver function but was euthanized on POD 8 because of worsening LFTs. Pathology revealed C4d positivity, extensive hemorrhagic necrosis, and a focal cytomegalovirus inclusion. Baboon 4 was clinically well with stable LFTs until POD29, when euthanasia was again necessitated by plantar ulcerations and rising LFTs. Final pathology was C4d negative and without evidence of rejection, inflammation, or thrombotic microangiopathy. Thus, nearly 1‐mo rejection‐free survival has been achieved following LXT in two of four consecutive recipients, demonstrating that the porcine liver can support life in primates for several weeks and has encouraging potential for clinical application as a bridge to allotransplantation for patients with acute‐on‐chronic or fulminant hepatic failure.